

Yuan-Kai Shi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3996164/yuan-kai-shi-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

130
papers

4,151
citations

25
h-index

63
g-index

155
ext. papers

5,521
ext. citations

5.5
avg, IF

5.47
L-index

#	Paper	IF	Citations
130	A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). <i>Journal of Thoracic Oncology</i> , 2014 , 9, 154-62	8.9	757
129	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. <i>Lancet Oncology, The</i> , 2016 , 17, 577-89	21.7	691
128	Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. <i>Lancet Oncology, The</i> , 2013 , 14, 953-61	21.7	307
127	The global implications of diabetes and cancer. <i>Lancet, The</i> , 2014 , 383, 1947-8	40	258
126	Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 1569-1575	13.4	218
125	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 867-875	8.9	141
124	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). <i>British Journal of Cancer</i> , 2018 , 118, 654-661	8.7	121
123	Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology,the</i> , 2019 , 6, e12-e19	14.6	107
122	Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. <i>Lancet Respiratory Medicine,the</i> , 2018 , 6, 681-690	35.1	103
121	Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study. <i>PLoS ONE</i> , 2015 , 10, e0143515	3.7	94
120	Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 69	22.4	85
119	Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1539-1548	8.9	85
118	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. <i>ESMO Open</i> , 2017 , 2, e000219	6	62
117	Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). <i>Journal of Hematology and Oncology</i> , 2020 , 13, 143	22.4	61
116	Plasma levels of heat shock protein 90 alpha associated with lung cancer development and treatment responses. <i>Clinical Cancer Research</i> , 2014 , 20, 6016-22	12.9	58
115	Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances. <i>Leukemia</i> , 2021 , 35, 312-332	10.7	52
114	Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. <i>American Journal of Hematology</i> , 2018 , 93, 607-614	7.1	45

113	Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. <i>Endocrine-Related Cancer</i> , 2015 , 22, 877-87	5.7	40
112	miR-130a regulates macrophage polarization and is associated with non-small cell lung cancer. <i>Oncology Reports</i> , 2015 , 34, 3088-96	3.5	36
111	Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study. <i>Chemotherapy</i> , 2007 , 53, 44-50	3.2	35
110	Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019 , 31, 152-161	3.8	31
109	A microRNA signature predicts survival in early stage small-cell lung cancer treated with surgery and adjuvant chemotherapy. <i>PLoS ONE</i> , 2014 , 9, e91388	3.7	28
108	Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018 , 122, 32-37	5.9	27
107	Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. <i>Thoracic Cancer</i> , 2019 , 10, 551-556	3.2	25
106	Chinese guidelines on the diagnosis and treatment of primary lung cancer (2015 version). <i>Cancer</i> , 2015 , 121 Suppl 17, 3165-81	6.4	25
105	Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts. <i>PLoS ONE</i> , 2014 , 9, e89848	3.7	24
104	Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 678-689	21.7	24
103	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 1569-1579	4.9	24
102	Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study. <i>European Journal of Cancer</i> , 2020 , 130, 182-192	7.5	23
101	Prognostic impact of mutation profiling in patients with stage II and III colon cancer. <i>Scientific Reports</i> , 2016 , 6, 24310	4.9	21
100	Current status and progress of lymphoma management in China. <i>International Journal of Hematology</i> , 2018 , 107, 405-412	2.3	20
99	VTE Risk Profiles and Prophylaxis in Medical and Surgical Inpatients: The Identification of Chinese Hospitalized Patients' Risk Profile for Venous Thromboembolism (Dissolve-2)-A Cross-sectional Study. <i>Chest</i> , 2019 , 155, 114-122	5.3	20
98	The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy. <i>PLoS ONE</i> , 2014 , 9, e84501	3.7	19
97	Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. <i>Oncologist</i> , 2019 , 24, e1251-e1261	5.7	19
96	Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type. <i>Annals of Hematology</i> , 2017 , 96, 1477-1483	3	15

95	Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study. <i>Anti-Cancer Drugs</i> , 2013 , 24, 641-7	2.4	15
94	Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients. <i>Theranostics</i> , 2020 , 10, 6399-6410	12.1	14
93	Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors. <i>JAMA Network Open</i> , 2020 , 3, e2013201	10.4	13
92	Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified. <i>Annals of Hematology</i> , 2017 , 96, 245-251	3	12
91	Reply to □ promoter polymorphism in the CASP8 gene is not associated with cancer risk □ <i>Nature Genetics</i> , 2008 , 40, 260-261	36.3	12
90	PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7506-7506	2.2	12
89	Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 7	22.4	11
88	The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study. <i>PLoS ONE</i> , 2015 , 10, e0142500	3.7	11
87	Anti-p53 autoantibody in blood as a diagnostic biomarker for colorectal cancer: A meta-analysis. <i>Scandinavian Journal of Immunology</i> , 2020 , 91, e12829	3.4	11
86	Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, e204429	13.4	11
85	Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study. <i>Targeted Oncology</i> , 2019 , 14, 149-158	5	10
84	Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 9	22.4	10
83	Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure. <i>Cancer Science</i> , 2018 , 109, 3943-3952	6.9	10
82	Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas. <i>Hematology</i> , 2016 , 21, 536-41	2.2	9
81	Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study. <i>Blood</i> , 2019 , 134, 1568-1568	2.2	8
80	Third-line treatment: A randomized, double-blind, placebo-controlled phase III ALTER-0303 study □ efficacy and safety of anlotinib treatment in patients with refractory advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9053-9053	2.2	8
79	Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study. <i>Japanese Journal of Clinical Oncology</i> , 2015 , 45, 569-75	2.8	7
78	Co-mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2019 , 23, 6812-6821	5.6	7

77	Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma. <i>Chinese Journal of Cancer</i> , 2015 , 34, 522-30		7
76	Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: A pilot study. <i>Molecular and Clinical Oncology</i> , 2014 , 2, 87-92	1.6	7
75	Whole-genome sequencing of prostate cancer reveals novel mutation-driven processes and molecular subgroups. <i>Life Sciences</i> , 2020 , 254, 117218	6.8	7
74	Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 2413-2424	7.4	7
73	Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1857-1870	8.9	7
72	A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients. <i>Cancer Medicine</i> , 2016 , 5, 1116-24	4.8	6
71	Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7596-7596	2.2	6
70	Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6061-6061	2.2	6
69	Phase 3 study of first-line crizotinib vs pemetrexed+isplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9058-9058	2.2	6
68	China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). <i>Annals of Translational Medicine</i> , 2015 , 3, 260	3.2	6
67	Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial. <i>Cancer Communications</i> , 2021 , 41, 889-903	9.4	6
66	Clinicopathologic characteristics and outcome of patients with different EGFR mutations. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019 , 15, 166-171	1.9	6
65	The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2014 , 38, 1291-8	2.7	5
64	Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: A retrospective study. <i>Thoracic Cancer</i> , 2013 , 4, 109-116	3.2	5
63	Effect of JS001, a monoclonal antibody targeting programmed death-1 (PD-1), on responses and disease control in patients with advanced or refractory alveolar soft part sarcoma: Results from a phase 1 trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11572-11572	2.2	5
62	Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2015 , 27, 239-46	3.8	5
61	Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association. <i>Cancer Biology and Medicine</i> , 2020 , 17, 896-909	5.2	5
60	Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases. <i>Current Cancer Drug Targets</i> , 2019 , 19, 666-673	2.8	5

59	China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). <i>Journal of Thoracic Disease</i> , 2015 , 7, E468-72	2.6	5
58	Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup. <i>International Journal of Cancer</i> , 2020 , 147, 2611-2620	7.5	4
57	Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases. <i>Oncology Research</i> , 2020 , 28, 127-133	4.8	4
56	Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial. <i>Cancer Communications</i> , 2018 , 38, 31	9.4	4
55	Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas. <i>Chinese Medical Journal</i> , 2015 , 128, 2498-504	2.9	4
54	Phase II trial of paclitaxel-carboplatin with intercalated gefitinib for untreated, epidermal growth factor receptor gene mutation status unknown non-small cell lung cancer. <i>Thoracic Cancer</i> , 2014 , 5, 149-154	3.2	4
53	Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7559-7559	2.2	4
52	Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era. <i>Oncotarget</i> , 2016 , 7, 72219-72228	3.3	4
51	First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 6	22.4	3
50	Plasma Lipidomic Analysis to Identify Novel Biomarkers for Hepatocellular Carcinoma. <i>Journal of Analysis and Testing</i> , 2017 , 1, 223-232	3.2	3
49	Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy. <i>Journal of Translational Medicine</i> , 2019 , 17, 339	8.5	3
48	Analysis of clinicopathological features of the echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase fusion gene in Chinese patients with advanced non-small-cell lung cancer. <i>Thoracic Cancer</i> , 2014 , 5, 255-60	3.2	3
47	Subgroup analysis of elderly patients (pts) in ALTER0303: Anlotinib hydrochloride as 3rd-line and further line treatment in refractory advanced NSCLC pts from a randomized, double-blind, placebo-controlled phase III ALTER0303 trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21181-e21181	2.2	3
46	Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. <i>Lung Cancer</i> , 2020 , 150, 240-246	5.9	3
45	Validation of the IMPROVE bleeding risk score in Chinese medical patients during hospitalization: Findings from the dissolve-2 study. <i>The Lancet Regional Health - Western Pacific</i> , 2020 , 4, 100054	5	3
44	A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report. <i>OncoTargets and Therapy</i> , 2021 , 14, 2741-2746	4.4	3
43	Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: A comprehensive analysis of 358 patients. <i>Thoracic Cancer</i> , 2021 , 12, 1943-1951	3.2	3
42	Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2016 , 9, 2911-7	4.4	3

41	P2.03a-001 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2017 , 12, S886-S887	8.9	2
40	CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial. <i>Cancer Communications</i> , 2019 , 39, 28	9.4	2
39	Chinese perspective of the role of primary care in cancer control. <i>Lancet Oncology, The</i> , 2015 , 16, 1227-821.7	21.7	2
38	Prognostic significance of baseline neutrophil-lymphocyte ratio in patients with non-small-cell lung cancer: a pooled analysis of open phase III clinical trial data.. <i>Future Oncology</i> , 2022 ,	3.6	2
37	An open-label, randomized, multicenter, phase III study of S-1 and cisplatin versus docetaxel and cisplatin in patients with untreated advanced non-small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8039-8039	2.2	2
36	Sintilimab (IBI308) in relapsed/refractory classical Hodgkin lymphoma: A multicenter, single-arm phase 2 trial in China (ORIENT-1 study).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7536-7536	2.2	2
35	Medication Therapy of High-Dose Methotrexate: An Evidence-Based Practice Guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	2
34	Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2015 , 27, 516-23	3.8	2
33	Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	2
32	Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era. <i>Chinese Medical Journal</i> , 2016 , 129, 2780-2785	2.9	2
31	Icotinib as initial treatment in lung adenocarcinoma patients with brain metastases. <i>Thoracic Cancer</i> , 2016 , 7, 437-41	3.2	2
30	Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in China. <i>BMJ Open</i> , 2019 , 9, e028589	3	1
29	Ventana immunohistochemistry ALK (D5F3) detection of ALK expression in pleural effusion samples of lung adenocarcinoma. <i>Personalized Medicine</i> , 2015 , 12, 349-357	2.2	1
28	Study of conditioning regimens with or without high-dose radiotherapy before autologous stem cell transplantation for treating aggressive lymphoma. <i>International Journal of Hematology</i> , 2009 , 89, 106-112	2.3	1
27	Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial.. <i>Signal Transduction and Targeted Therapy</i> , 2022 , 7, 25	21	1
26	Comprehensive gene copy number alterations profiling predict efficacy of adjuvant chemotherapy in resected stage II-IIIa lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e24278-e24278	2.2	1
25	Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9077-9077	2.2	1
24	Characteristics and Management of -Mutated Diffuse Large B-Cell Lymphoma Patients. <i>Cancer Management and Research</i> , 2020 , 12, 11515-11522	3.6	1

23	Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial. <i>Thoracic Cancer</i> , 2021 , 12, 2345-2351	3.2	1
22	Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study.. <i>Chinese Medical Journal</i> , 2021 , 135, 433-440	2.9	1
21	The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: An analysis of 1007 patients in the rituximab era. <i>Leukemia Research</i> , 2021 , 110, 106715	2.7	1
20	Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy. <i>Journal of Translational Medicine</i> , 2021 , 19, 399	8.5	0
19	Efficacy of icotinib in lung squamous-cell cancer: A real-world experience from single institution. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017 , 13, 379-384	1.9	
18	In response. <i>Journal of Thoracic Oncology</i> , 2014 , 9, e58-e59	8.9	
17	In vitro study on cryopreservation of peripheral blood stem cells with uncontrolled freezer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2002 , 14, 235-239	3.8	
16	High dose chemoradiotherapy with autologous hematopoietic stem cell transplantation in the treatment of advanced Hodgkin's lymphoma: A report of 11 cases. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2002 , 14, 251-258	3.8	
15	Rh-endostatin combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in NSCLC: A retrospective comparison with standard chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21198-e21198	2.2	
14	Plinabulin (Plin), a small molecule with anti-cancer activity and a novel mechanism of action (MoA) in docetaxel (Tax)-induced neutropenia: Phase II results from a head-to-head comparison with Pegfilgrastim (Peg).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2528-2528	2.2	
13	BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21108-e21108	2.2	
12	The genome patterns of prostate cancer in national cancer center in China.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e17090-e17090	2.2	
11	A phase II trial with the combination of plinabulin (plin) pegfilgrastim (peg): Evaluation of the reversal of peg's immune-suppressive potential by the addition of plin to peg.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4-4	2.2	
10	Autologous peripheral blood stem cell mobilization following high-dose CHOP chemotherapy combined with rituximab in patients with NHL.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e18003-e18003	2.2	
9	Comprehensive analysis of driver mutations in Chinese squamous cell lung carcinomas by targeted next-generation sequencing.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 7544-7544	2.2	
8	Comprehensive genomic profiling of 443 patients with advanced renal cell carcinoma (RCC) to reveal clinically relevant genomic alterations and to aid in classification of rare subtypes.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e19048-e19048	2.2	
7	Apatinib plus icotinib in treating advanced non-small-cell lung cancer after icotinib treatment failure.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20528-e20528	2.2	
6	Whole exome sequencing identifies novel prognostic biomarker in colon cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15098-e15098	2.2	

- 5 An updated analysis of ICOGEN to demonstrate utility of a blood-based proteomic test to predict outcomes in EGFR TKI treated patients.. *Journal of Clinical Oncology*, **2017**, 35, e20655-e20655 2.2
- 4 Dynamic process of circulating tumour DNA (ctDNA) profiling as a predictor of efficacy of pemetrexed combined platinum chemotherapy in advanced lung adenocarcinoma.. *Journal of Clinical Oncology*, **2017**, 35, e23048-e23048 2.2
- 3 Phase I/II trial of sorafenib combined with FOLFOX4 in untreated patients with advanced gastric adenocarcinoma: Phase I results.. *Journal of Clinical Oncology*, **2012**, 30, e14606-e14606 2.2
- 2 Development and validation of a UHPLC-MS/MS method for simultaneous quantitation the plasma concentration of Sabarubicin and its alcohol metabolite M3 in Chinese small cell lung cancer patients. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2016**, 1425-1432 3.2
- 1 Recombinant human thrombopoietin prior to mobilization chemotherapy facilitates platelet recovery in autologous transplantation in patients with lymphoma: Results of a prospective randomized study. *Chronic Diseases and Translational Medicine*, **2021**, 7, 190-198 3.9